-
公开(公告)号:US09744170B2
公开(公告)日:2017-08-29
申请号:US15073767
申请日:2016-03-18
Applicant: AbbVie Inc.
Inventor: Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K9/24
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
公开(公告)号:US20190275051A1
公开(公告)日:2019-09-12
申请号:US16239199
申请日:2019-01-03
Applicant: AbbVie Inc.
Inventor: Nathaniel Catron , David Lindley , Jonathan M. Miller , Eric A. Schmitt , Ping Tong
IPC: A61K31/5377 , A61K9/48 , A61K31/496 , A61K31/437 , A61K9/14 , A61K9/16
Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号:US08940759B2
公开(公告)日:2015-01-27
申请号:US14107559
申请日:2013-12-16
Applicant: AbbVie Inc.
Inventor: Geoff G. Zhang , Douglas H. Hoffman , Jonathan M. Miller
IPC: A01N43/42 , A61K31/44 , C07D471/02 , C07D491/02 , C07D498/02 , C07D513/02 , C07D515/02 , C07D495/04
CPC classification number: C07D495/04
Abstract: Citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
Abstract translation: 噻吩并[3,2-c]吡啶-3-基}苯基)-N(4- {4-氨基-7- [1-(2-羟乙基)-1H-吡唑-4-基] ' - (3-氟苯基)脲及其结晶形式是用于治疗疾病例如癌症的药物组合物的合适的药物成分。
-
公开(公告)号:US10213433B2
公开(公告)日:2019-02-26
申请号:US14537392
申请日:2014-11-10
Applicant: AbbVie Inc.
Inventor: Nathaniel Catron , David Lindley , Jonathan M. Miller , Eric A. Schmitt , Ping Tong
IPC: A61K31/397 , A61K31/5377 , A61K9/14 , A61K9/16 , A61K9/48 , A61K31/437 , A61K31/496
Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号:US20170368066A1
公开(公告)日:2017-12-28
申请号:US15639424
申请日:2017-06-30
Applicant: AbbVie Inc.
Inventor: Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K47/38 , A61K31/4025 , A61K9/24 , A61K31/427 , A61K31/497 , A61K47/32
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
公开(公告)号:US20170197980A1
公开(公告)日:2017-07-13
申请号:US15321153
申请日:2015-06-25
Applicant: AbbVie Inc.
Inventor: Lloyd S. Dias , Rodney James Ketner , Jonathan M. Miller , Warren Kenyon Miller , Michael Mark Morgen , Brice George Murri , David Thomas Vodak
IPC: C07D495/04 , C07C309/17
CPC classification number: C07D495/04 , C07C309/17
Abstract: Docusate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.
-
公开(公告)号:US20160199374A1
公开(公告)日:2016-07-14
申请号:US15073767
申请日:2016-03-18
Applicant: AbbVie Inc.
Inventor: Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K47/38 , A61K31/427 , A61K47/32 , A61K31/497 , A61K31/4025
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
-
公开(公告)号:US20250161318A1
公开(公告)日:2025-05-22
申请号:US18809439
申请日:2024-08-20
Applicant: AbbVie Inc.
Inventor: Nathaniel Catron , David Lindley , Jonathan M. Miller , Eric A. Schmitt , Ping Tong
IPC: A61K31/5377 , A61K9/14 , A61K9/16 , A61K9/48 , A61K31/437 , A61K31/496
Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
公开(公告)号:US20150258093A1
公开(公告)日:2015-09-17
申请号:US14677611
申请日:2015-04-02
Applicant: AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
Inventor: Jonathan M. Miller , John B. Morris , Nancy E. Sever , Eric A. Schmitt , Ping X. Gao , Yi Shi , Yi Gao , Bernd Liepold , Anna Moosmann , Mirko Pauli , Fatih Durak , Thomas Kessler , Peter A. Hoelig , Karin Rosenblatt , Drazen Kostelac , Rajeev Gokhale , Mark Costello , Carl Knable
IPC: A61K31/513 , A61K31/4025 , A61K31/427 , A61K31/497
CPC classification number: A61K31/513 , A61K9/209 , A61K31/4025 , A61K31/427 , A61K31/497 , A61K47/32 , A61K47/38 , A61K2300/00
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Abstract translation: 本公开涉及包含抗病毒化合物的固体剂型和使用这些剂型来治疗抗病毒感染的方法。
-
公开(公告)号:US20220125796A1
公开(公告)日:2022-04-28
申请号:US17341158
申请日:2021-06-07
Applicant: AbbVie Inc.
Inventor: Nathaniel Catron , David Lindley , Jonathan M. Miller , Eric A. Schmitt , Ping Tong
IPC: A61K31/5377 , A61K9/16 , A61K9/14 , A61K31/496 , A61K31/437 , A61K9/48
Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
-
-
-
-
-
-
-
-
-